Three Key Takeaways from the 43rd Annual J.P. Morgan Healthcare Conference
Radiotherapy, China's biotech surge and AI's role in drug discovery are notable topics that emerged from conversations on the ground floor.
Genetic Medicines Biotech Dyne Pulls In $345M for Clinical Tests of Muscle Drugs
Dyne Therapeutics recently reported encouraging Phase 1/2 clinical data in myotonic dystrophy type 1 and Duchenne muscular dystrophy. At the J.P. Morgan Healthcare Conference, CEO Joshua Brumm said Dyne’s existing cash combined with the new capital is expected to last through 2025—well beyond the next key milestones for both therapeutic candidates.
Using Data to Help Healthcare Practices Succeed
A new report from Relatient, A Data-Driven Guide to Patient Access Succes, highlights how focusing on data accuracy and relevance can enhance the performance of healthcare practices.
Biogen Bows Out of Acorda Pact on MS Med; Focus Turns to New Growth Drivers
Generic competition has eroded sales of multiple sclerosis drug Ampyra, marketed as Fampyra outside the U.S. Biogen told Acorda Therapeutics that it’s terminating its ex-U.S. rights to Fampyra in order to focus on other priorities, which include expanding beyond MS.
At JPM, Top GSK Cancer Executive Talks Drug Targets and Oncology Strategy
Though GSK divested much of its oncology assets to Novartis in 2015, the company has built back through a internal R&D and business development deals. GSK Senior Vice President, Global Head of Oncology, R&D Hesham Abdullah explained the company’s evolving cancer strategy in an interview during the J.P. Morgan Healthcare Conference in San Francisco.
J&J Joins the Cancer ADC Dealmaking Spree With $2B Ambrx Acquisition
Johnson & Johnson’s acquisition of antibody drug conjugate developer Ambrx Biopharma comes as Novartis and Merck also unveiled M&A deals on the first day of the J.P. Morgan Healthcare conference. In a report, the bank said big pharmas are looking for deals involving de-risked assets.
What tools do payers have to advance health equity? Here’s what BCBS of Massachusetts is leveraging
Blue Cross Blue Shield of Massachusetts is leveraging data and value-based contracts to reduce disparities it has observed and publicly revealed within its own patient population, while also providing financial support to groups that help physicians address health equity.
presented by
Transforming Patient Care: The Role of AI-Powered Assistants
The progress in artificial intelligence (AI) is reshaping patient care, across various dimensions, from facilitating faster discharge to curating treatment plans and suggesting lifestyle changes.
JPM conference further heightened investor interest in data-driven solutions
Providers, payers, and life sciences companies have a lot of room for growth using AI, and investors participating in JPM will continue to focus on companies that recognize this and act on it.
Pfizer, Bayer each strike up deals to add in-vivo gene editing to pipeline mix
As the annual J.P. Morgan HealthCare Conference kicked off Monday, two pharma giants unveiled deals that give them access to in-vivo gene editing technologies. Pfizer is teaming up with Beam Therapeutics to develop new base-editing therapies while Bayer hopes to develop new medicines with the in-vivo CRISPR editing tools of Mammoth Biosciences.
Medtronic CEO expects to submit renal denervation data to FDA this year, overcoming previous failures
Medtronic suffered a shocking setback back in 2014 when its Symplicity 3 pivotal trial failed to meet its primary endpoint of reducing blood pressure meaningfully. Now it is gearing up to present new data to the FDA.
For CAR-Ts to be successful, figuring out manufacturing is key
Efficacy, safety and reimbursement are all important things for CAR-T makers to figure out, but manufacturing is no less important.
The Funding Model for Cancer Innovation is Broken — We Can Fix It
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
Cell, gene therapies demand creative payment models, but implementing them is a challenge, CEOs say
Performance- and time-based payment models - like the one bluebird bio has proposed for LentiGlobin - are especially harder to put into practice in the US than in Europe, some executives said at this week's JPM conference.
What does the $74B BMS-Celgene deal mean for 2019? Investors at JPM weigh in
After a bruising second half of the year, more biotech companies could be targeted for buys, along with the possibility of additional large deals.
Biopharma, healthcare CEOs tout value-based care at JPM
Fully incorporating value into pricing will require significant effort and investment, the Novartis CEO said. Meanwhile, CVS/Caremark's Larry Merlo said the company's acquisition of Aetna opened opportunities for innovative pricing models.
Lilly chief at JPM: conditions ‘ripe’ for M&A uptick in 2019
CEO David Ricks advocates careful approach focused on differentiation of assets in breakout session, while CFO says company has capacity for one transaction per quarter.
Foundation Medicine appoints new CEO; exec provides forecasts for precision medicine in 2019
With the approval of Loxo's Vitrakvi, pan-cancer drugs and an emphasis on real-world data are likely to become important trends trends this year.